Format

Send to

Choose Destination
Eur Heart J. 2010 Aug;31(15):1828-35. doi: 10.1093/eurheartj/ehq220. Epub 2010 Jul 7.

Shock in acute myocardial infarction: the Cape Horn for trials?

Author information

1
Department of Internal Medicine/Cardiology, University of Leipzig-Heart Center, Str├╝mpellstrasse 39, Leipzig, Germany. thielh@medizin.uni-leipzig.de

Abstract

Despite therapeutic improvements, cardiogenic shock (CS) remains the most common cause of death in patients with acute myocardial infarction (AMI). In addition to percutaneous coronary intervention, inotropes, fluids, adjunctive medication, intra-aortic balloon counterpulsation, and also assist devices are widely used for treatment. However, currently, there is only limited evidence for any of the above treatments. This review will therefore outline the underlying causes, pathophysiology, and treatment of CS complicating AMI with major focus on interventional techniques and advancement of new therapeutical arsenals, both pharmacological and mechanical.

PMID:
20610640
DOI:
10.1093/eurheartj/ehq220
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center